Myriad Genetics Inc(MYGN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.2 | Insider Own | 7.37% | Shs Outstand | 95.6M | Perf Week | 13.54% |
| Market Cap | 0.60B | Forward P/E | - | EPS next Y | 18.26% | Insider Trans | -0.11% | Shs Float | 88.6M | Perf Month | 48.35% |
| Enterprise Value | 0.70B | PEG | - | EPS next Q | -0.2 | Inst Own | 94.19% | Short Float | 10.46% | Perf Quarter | 24.8% |
| Income | -0.11B | P/S | 0.75 | EPS this Y | -1300.31% | Inst Trans | -4.45% | Short Ratio | 3.58 | Perf Half Y | 29.96% |
| Sales | 0.81B | P/B | 1.98 | EPS next 5Y | - | ROA | -17.11% | Short Interest | 9.27M | Perf YTD | 2.28% |
| Book/sh | 3.18 | P/C | 5.22 | EPS past 3/5Y | -41.67% -8.03% | ROE | -32.54% | 52W High | -26% ($8.50) | Perf Year | -22.35% |
| Cash/sh | 1.2 | P/FCF | - | Sales past 3/5Y | 6.72% 5.24% | ROIC | -22.2% | 52W Low | 129.56% ($2.74) | Perf 3Y | -54.78% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 72.02% | Gross Margin | 65.1% | Volatility(W/M) | 6.22% 6.71% | Perf 5Y | -79.47% |
| Dividend TTM | - | EV/Sales | 0.86 | Sales Y/Y TTM | -3.16% | Oper. Margin | -11.22% | ATR (14) | 0.36 | Perf 10Y | -67.98% |
| Dividend Ex-Date | - | Quick Ratio | 1.98 | EPS Q/Q | 87.25% | Profit Margin | -13.96% | RSI (14) | 78.69 | Recom | 3.11 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.21 | Sales Q/Q | -10.51% | SMA20 | 33.08% ($4.73) | Beta | 1.69 | Target Price | $4.49 |
| Payout | - | Debt/Eq | 0.69 | Earnings | 2026/11/4 | SMA50 | 57.02% ($4.01) | Rel Volume | 0.87 | Prev Close | $6.02 |
| Employees | 2700 | LT Debt/Eq | 0.67 | EPS/Sales Surpr. | -332.53% -7.44% | SMA200 | 36.62% ($4.6) | Avg Volume(3M) | 2.59M | Price | $6.29 |
| IPO | 1995/10/6 | Option/Short | Yes/Yes | Trades | 8304 | Volume | 2,244,268 | Change | 4.49% |
🧬 A US-based precision diagnostics company specializing in hereditary cancer testing and molecular diagnostics. As a pioneer in gene-based cancer diagnostic testing, it offers a molecular diagnostics portfolio that includes hereditary cancer risk testing (MyRisk), mental health drug response testing (GeneSight), and prenatal testing, and operates across the oncology, women's health, and mental health segments.
Over the past 1 year, roughly in the middle
26% below its 1-year high.
Traded about as much as usual. That is 87% of its average volume.
Next earnings report: November 4
7 days to go.
MYGN has a sound balance sheet but weak earning power
Of every $100 in sales, $11.22 is lost.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -1300.3% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $75. Peers typically go for $451.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -79.5%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 94.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #31 of 44 in the industry
Based on market cap of $602M.
FRNM#28 Freenome Inc $1B PER - 
OPK#29 Opko Health Inc $1B PER - 
CSTL#30 Castle Biosciences Inc $1B PER - MYGN#31 Myriad Genetics Inc $602M PER - 
FLGT#32 Fulgent Genetics Inc $570M PER - 
FAQ
What kind of company is MYGN?
MYGN belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of MYGN?
The market cap of MYGN is approximately $602M, ranking 2,995 within its sector.
What is the 52-week high and low for MYGN?
MYGN has recorded a 52-week high of $8.50 and a low of $2.74.
